September 16, 2022

D-RD APPEARS TO IMPROVE LONG-TERM OUTCOMES IN NEWLY DIAGNOSED, TRANSPLANT-INELIGIBLE MYELOMA

Among patients with newly diagnosed, transplant-ineligible patients with multiple myeloma (MM), adding daratumumab to lenalidomide and dexamethasone (D-Rd) appears to improve long-term outcomes, according to research presented at the 19th Annual Meeting and Exposition International Myeloma Society.

Read more here.